Eating Rehabilitation Training for Timely Removal of Nasogastric Tube in Elderly Patients (NCT05810688) | Clinical Trial Compass
UnknownNot Applicable
Eating Rehabilitation Training for Timely Removal of Nasogastric Tube in Elderly Patients
Taiwan96 participantsStarted 2023-02-21
Plain-language summary
Aspiration pneumonia is a common complication in senior patients with high morbidity and mortality rate. The decline of physical function among elders can easily lead to swallowing disorders, and nasogastric (NG) tube insertion is an emergency medical treatment that provides patients with adequate hydration and nutrition. However, NG is easily dislodged after a long duration of placement; furthermore, lacking accurate feeding skills could also lead to aspiration pneumonia.
Who can participate
Age range
75 Years – 110 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients than or equal to 75 years old
. Clear consciousness
. Diagnosed with aspiration pneumonia (the main diagnostic disease code is ICD-9-CM: 507; ICD-10-CM: J69)
. Those who were hospitalized for more than 24 hours and had a nasogastric tube inserted for the first time within 1 month
. Those who can communicate in Chinese or Taiwanese
. The doctor judges that the condition is stable, such as: body temperature \< 37.5°C, heart rate \< 100 beats/min, respiratory rate \< 24/min, systolic blood pressure \> 90 mmHg and fingertip pulse oximeter saturation greater than 90%
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
nasogastric tube successfully removed and spent of time with removed successfully nasogastric tube
Timeframe: From date of randomization until the date of discharge from the cause, assessed up to one month.
Trial details
NCT IDNCT05810688
SponsorNational Taipei University of Nursing and Health Sciences
. Patients who have been placed in a nasogastric tube or gastrostomy for force-feeding before seeing a doctor
. Diagnosed with other neurological disorders, such as Parkinson's disease, multiple sclerosis, polio, dermatomyosclerosis inflammation, and myasthenia gravis